Mannose 6-phosphate/insulin-like growth factor 2 receptor, a Bona fide tumor suppressor gene or just a promising candidate?
Mannose 6-phosphate/insulin-like growth factor 2 receptor, a Bona fide tumor suppressor gene or just a promising candidate?
复制标题
DOI：
10.1023/a:1009571417429
复制
发表时间：
2000-01-01
影响因子：
2.5
通讯作者：
Elli, MJ
中科院分区：
文献类型：
--
作者：
DaCosta, SA;Schumaker, LM;Elli, MJ
甘露糖6-磷酸/胰岛素样生长因子2受体（M6 P/ICF 2 R）（3）被认为是“候选”肿瘤抑制基因。这一假说是由乳腺癌和肝癌中染色体6 q26上M6 P/IGF 2 R位点的杂合性缺失（洛）的鉴定引起的，伴随着其余等位基因的点突变。编码区微卫星的体细胞突变也在胃肠道、子宫内膜和大脑的复制错误阳性（RER+）肿瘤中得到描述。这些基因数据是令人信服的，但肿瘤抑制基因候选人必须满足功能和遗传标准。这篇综述权衡了证据，并讨论了必要的意见，以促进M6 P/ICF 2 R从候选真正的肿瘤抑制基因。
The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/ICF2R)(3) is considered a "candidate" tumor suppressor gene. This hypothesis has been provoked by the identification of loss of heterozygosity (LOH) at the M6P/IGF2R locus on chromosome 6q26 in breast and liver cancer, accompanied by point mutations in the remaining allele. Somatic mutations in coding region microsatellites have also been described in replication error positive (RER+) tumors of the gastrointestinal tract, endometrium and brain. These genetic data are compelling, but a tumor suppressor gene candidate has to meet functional as well as genetic criteria. This review weighs the evidence and discusses the observations that are necessary to promote M6P/ICF2R from candidate to bona fide tumor suppressor gene.